Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).
Criteria: * Patients must have pathologically confirmed non-small cell lung cancer * Early Stage NSCLC Stage IA2 - IIA (tumor size \> 1cm and ≤ 5cm, N0M0), select IIB (tumor size \>5cm and ≤ 7cm, N0M0). Multiple (up to 2) primary lung cancers allowed. Isolated parenchymal recurrences (tumor size ≤ 7cm and up to 2 separate ipsilateral lesions) of initially TanyN0M0 disease. ° Note: The determination of two primary NSCLCs will be based on pathologic and genomic differentiation. * No known sensitizing EGFR or ALK alterations * Disease amenable to 3, 5 or 8 fraction SBRT as judged by treating…
Radiation therapy to start within 28 days after enrollment. Radiation therapy will be performed in accordance with institutional standard practice. Proton therapy and photon therapy are allowed as per standard of care in accordance with institutional practice.
Ivonescimab every 3 weeks on Day 1 of each Cycle as an intravenous (IV).